HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenblatt, D. J. Articles by Karim, A. Search for Related Content PubMed Articles by Greenblatt, D. J. Articles by Karim, A.

Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT₁ and MT₂

From the Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts–New England Medical Center, Boston, Massachusetts (Dr Greenblatt, Mr Harmatz) and Takeda Global Research and Development Center, Deerfield, Illinois (Dr Karim).

Effects of age and gender on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic acting via binding to melatonin MT₁ and MT₂ receptors, were evaluated in healthy young (18-34 years) and elderly (63-79 years) volunteers. Part 1 evaluated the pharmacokinetics of open-label oral ramelteon, 16 mg. Part 2 was a double-blind, randomized, 2-trial crossover pharmacodynamic study of 16-mg ramelteon and matching placebo. Ramelteon clearance was significantly reduced in elderly vs young volunteers (384 vs 883 mL/min/kg, P < .01) and half-life significantly increased (1.9 vs 1.3 h, P < .001). Gender did not significantly influence clearance or half-life. Ramelteon was extensively transformed to its hydroxylated M-II metabolite, with serum AUC values averaging about 30 times those of the parent drug. Compared to placebo, ramelteon increased self- and observer-rated sedation, but age and gender did not influence the magnitude of the ramelteon-placebo difference. Ramelteon did not significantly impair digit-symbol substitution test performance or impair information acquisition and recall. Thus, the reduced clearance and higher serum levels of ramelteon in elderly subjects were not associated with enhanced pharmacodynamic effects. The usually recommended clinical dose of ramelteon (8 mg) does not require modification based on age or gender.

Key Words: Insomnia • ramelteon • CYP1A2 • pharmacokinetics • pharmacodynamics • age • gender

Address for reprints: David J. Greenblatt, MD, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111; e-mail: dj.greenblatt{at}tufts.edu.

This article has been cited by other articles:

				J. N Reynoldson, E. S. Elliott, and L. A. Nelson Ramelteon: A Novel Approach in the Treatment of Insomnia Ann. Pharmacother., September 1, 2008; 42(9): 1262 - 1271. [Abstract] [Full Text] [PDF]

				S. L. Markantonis, E. Tsakalozou, A. Paraskeva, C. Staikou, and A. Fassoulaki Melatonin Pharmacokinetics in Premenopausal and Postmenopausal Healthy Female Volunteers J. Clin. Pharmacol., February 1, 2008; 48(2): 240 - 245. [Full Text] [PDF]